Mehrdokht Mazdeh1, Mohammad Taheri2, Arezou Sayad2, Siamak Bahram3, Mir Davood Omrani2, Abolfazl Movafagh2, Hidetoshi Inoko4, Mohammad Taghi Akbari5, Rezvan Noroozi2, Mehrdad Hajilooi6, Ghasem Solgi6,7. 1. Department of Neuroogy, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. 2. Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. Centre de Recherche d'Immunologie et d'Hématologie, Universite de Strasbourg, Strasbourg, France. 4. Department of Genetic Information, Division of Molecular Life Science, Tokai University School of Medicine, Tokyo, Japan. 5. Tehran Medical Genetics Laboratory, Tehran, Iran. 6. Department of Immunology, School of Medicine, Hamadan University of Medical Sciences, Mahdieh Ave, Lona Park, Hamadan, Iran. 7. Molecular Immunology Research Group, Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Sh Fahmideh Blv, Lona Park, Hamadan, Iran.
Abstract
AIMS: This study investigated the influence of HLA class-I and -II genes in the response to IFN-β in relapsing-remitting multiple sclerosis (MS) patients. PATIENTS & METHODS: In this cohort, 231 relapsing-remitting MS patients who are classified into IFN-β responders (n = 146) and nonresponders (n = 85) and 180 ethnic-matched healthy controls were analyzed. Clinical outcome of IFN-β therapy particularly Expanded Disability Status Scale scores were evaluated in relation to HLA-A, -B and -DRB1 alleles and haplotypes. RESULTS: Increased frequencies of HLA-DRB1*04 allele and HLA-A*03-B*44-DRB1*04 haplotype, and decreased frequency of HLA-B*15 were associated with better response to IFN-β treatment. CONCLUSION: The possibility of genetic screening particularly HLA typing prior to starting IFN-β therapy for MS may permit the identification of likely responders or nonresponders.
AIMS: This study investigated the influence of HLA class-I and -II genes in the response to IFN-β in relapsing-remitting multiple sclerosis (MS) patients. PATIENTS & METHODS: In this cohort, 231 relapsing-remitting MSpatients who are classified into IFN-β responders (n = 146) and nonresponders (n = 85) and 180 ethnic-matched healthy controls were analyzed. Clinical outcome of IFN-β therapy particularly Expanded Disability Status Scale scores were evaluated in relation to HLA-A, -B and -DRB1 alleles and haplotypes. RESULTS: Increased frequencies of HLA-DRB1*04 allele and HLA-A*03-B*44-DRB1*04 haplotype, and decreased frequency of HLA-B*15 were associated with better response to IFN-β treatment. CONCLUSION: The possibility of genetic screening particularly HLA typing prior to starting IFN-β therapy for MS may permit the identification of likely responders or nonresponders.
Authors: Kaarina Kowalec; Elaine Kingwell; Robert Carruthers; Ruth Ann Marrie; Sasha Bernatsky; Anthony Traboulsee; Colin J D Ross; Bruce Carleton; Helen Tremlett Journal: BMJ Open Date: 2017-06-02 Impact factor: 2.692